PMC full text: | Clin Pharmacol Ther. Author manuscript; available in PMC 2014 Aug 1. Published in final edited form as: Clin Pharmacol Ther. 2014 Aug; 96(2): 169–174. Published online 2014 May 2. doi: 10.1038/clpt.2014.97 | << PrevFigure 1Next >> |
Figure 1
Workflow for interpreting G6PD genotype and for assessing the need for enzyme activity test. *It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified (14).
Clin Pharmacol Ther. 2014 Aug;96(2):169-74. doi: 10.1038/clpt.2014.97. Epub 2014 May 2.
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
Abstract
-.-.-
full-text from ► Clinical Pharmacogenetics Implementation Consortium
National Guideline Clearinghouse | Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of <em>G6PD</em> deficiency genotype.
Clinical Pharmacogenetics Implementation Consortium

Guideline Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context ofG6PD deficiency genotype.
Bibliographic Source(s)
Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014 Aug;96(2):169-74. [38 references] PubMed |
No hay comentarios:
Publicar un comentario